AgomAb Therapeutics (NASDAQ:AGMB) Research Coverage Started at Morgan Stanley

Morgan Stanley started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $28.00 price target on the stock.

Separately, Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Performance

Shares of AGMB opened at $14.21 on Tuesday. AgomAb Therapeutics has a one year low of $12.66 and a one year high of $17.45.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.